ABCD research and audit at the ADA

Author: 
Dr Bob Ryder (Website Co-ordinator, Clinical Lead, ABCD Nationwide Audits)
Author-field: 
Dr. Bob Ryder
Date of the announcement: 
Wednesday, 27 June, 2018
Body: 

ABCD has three posters at the current American Diabetes Association meeting in Orlando, Florida. The latest data from the ABCD study of Endobarrier in diabetes or pre-diabetes with obstructive sleep apnoea (End-OSA study) shows that 11/12 patients no longer require to wear their continuous positive airway pressure masks (CPAP) because of the weight loss from Endobarrier (click HERE to see the poster).  A cost effectiveness analysis from the first ABCD Endobarrier study, REVISE-Diabesity, showed that Endobarrier used with liraglutide was cost effective over two years (click HERE to see the poster).  ABCD has established an independent, worldwide, Endobarrier registry the first, albeit very early, analysis of data from this shows that the rate of the hepatic abscess complication is only 1% in contrast to the 3.5% rate found in the FDA trial which rate has caused worldwide worry about Endobarrier (click HERE to see the poster).  Of interest Dr Ryder also presented at the meeting data from the NHS Endobarrier service in Birmingham  which showed that during the year with Endobarrier the patients lost 15.8kg weight and HbA1C fell from 10% to 7.5% in a group of patients with long-standing poor diabetes control and obesity refractory to other therapies. The required dose of insulin reduced dramatically for those on insulin and one third of them no longer required insulin. Systolic blood pressure fell significantly as did markers of fatty liver. 6 months after removal 68% managed to maintain the improvement and of those who deteriorated 70% had depression (click HERE to see the poster).

User login